4-Oxazolecarboxylic acid, 2-cyclopropyl-, hydrazide | 1429559-37-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Oxazolecarboxylic acid, 2-cyclopropyl-, hydrazide
• 英文别名: 2-cyclopropyl-1,3-oxazole-4-carbohydrazide
• CAS: 1429559-37-4
• 化学式: C₇H₉N₃O₂
• 分子量: 167.17
• InChiKey: FOSUXIWGJXCQDZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  81.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF<br/>[FR] NOUVELLES N-ACYL-5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZINES 8-SUBSTITUÉES CHIRALES UTILISÉES COMME ANTAGONISTES SÉLECTIFS DES RÉCEPTEURS NK-3, COMPOSITION PHARMACEUTIQUE, PROCÉDÉS DESTINÉS À ÊTRE UTILISÉS DANS DES TROUBLES À MÉDIATION PAR LE RÉCEPTEUR NK-3 ET LEUR SYNTHÈSE CHIRALE
  申请人：EUROSCREEN SA

  公开号：WO2013050424A1

  公开（公告）日：2013-04-11

  The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

  本发明涉及公式I的新化合物及其在治疗治疗中的应用。该发明还涉及使用N-sp3保护基对5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪进行新的手性合成。该发明还提供了用于合成公式I化合物的中间体。
• NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF
  申请人：Euroscreen S.A.

  公开号：EP3029042A1

  公开（公告）日：2016-06-08

  The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

  本发明涉及式 I 的新型化合物 及其在治疗中的用途。本发明还涉及一种利用 N-sp3 保护基团手性合成 5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪的新方法。本发明还提供了用于合成式 I 化合物的中间体。
• Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
  申请人：Euroscreen S.A.

  公开号：US10065961B2

  公开（公告）日：2018-09-04

  The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

  本发明涉及式 I 的新型化合物及其在治疗中的应用。本发明还涉及一种利用 N-sp3 保护基团手性合成 5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪的新方法。本发明还提供了用于合成式 I 化合物的中间体。
• Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
  申请人：Ogeda SA

  公开号：US10683295B2

  公开（公告）日：2020-06-16

  The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

  本发明涉及式 I 的新型化合物及其在治疗中的应用。本发明还涉及一种利用 N-sp3 保护基团手性合成 5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪的新方法。本发明还提供了用于合成式 I 化合物的中间体。
• Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
  申请人：Ogeda SA

  公开号：US10941151B2

  公开（公告）日：2021-03-09

  The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

  本发明涉及式 I 的新型化合物及其在治疗中的应用。本发明还涉及一种利用 N-sp3 保护基团手性合成 5,6,7,(8-取代)-四氢-[1,2,4]三唑并[4,3-a]吡嗪的新方法。本发明还提供了用于合成式 I 化合物的中间体。